Serum NMR Profiling Reveals Differential Alterations in the Lipoproteome Induced by Pfizer-BioNTech Vaccine in COVID-19 Recovered Subjects and Naïve Subjects by Veronica Ghini, Veronica Ghini, Veronica Ghini, Laura Maggi, Alessio Mazzoni, Michele Spinicci, Michele Spinicci, Lorenzo Zammarchi, Lorenzo Zammarchi, Alessandro Bartoloni, Alessandro Bartoloni, Francesco Annunziato, Francesco Annunziato, Paola Turano, Paola Turano, Paola Turano

“…1H NMR spectra of sera have been used to define the changes induced by vaccination with Pfizer-BioNTech vaccine (2 shots, 21 days apart) in 10 COVID-19-recovered subjects and 10 COVID-19-naïve subjects at different time points, starting from before vaccination, then weekly until 7 days after second injection, and finally 1 month after the second dose. …”
Get full text

EVENTOS ADVERSOS À 3ª DOSE DAS VACINAS ASTRAZENECA E PFIZER EM UMA COORTE DE TRABALHADORES DA SAÚDE by Maria da Penha Gomes Gouvea, Isac Ribeiro Moulaz, Thayná Martins Gouveia, Beatriz Paoli Thompson, Karen Evelin Monlevade Lança, Bárbara Sthefany de Paula Lacerda, Gabriela Curto Cristianes Lacerda, João Pedro Gonçalvez Lenzi, João Pedro Moraes Miossi, Matheus Leite Rassele, Felipe de Castro Pimentel, Sabrina de Souza Ramos, Valéria Valim

Subjects: “…COVID-19 Vacinas Terceira dose AstraZeneca Pfizer…”
Get full text

Optic neuritis secondary to the Pfizer-BioNTech-162b2 COVID-19 vaccine managed with plasmapheresis: A case report and review by Paras P Shah, Samuel Gelnick, Daniel Zhu, Amanda Wong, Rashmi Verma

Get full text

Two cases with generalised bullous cutaneous reactions after COVID‐19 mRNA vaccine Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®) by Charlotte E. Rinnooy Kan, Heike Röckmann, Marijke R. vanDijk, Tanuja Ramsaransing, Lieke L. Reubsaet, Elke E. M. Peters, Lydia E. Vos

Subjects: Get full text

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) by Johannes Korth, Michael Jahn, Oliver Dorsch, Olympia Evdoxia Anastasiou, Burkhard Sorge-Hädicke, Ute Eisenberger, Anja Gäckler, Ulf Dittmer, Oliver Witzke, Benjamin Wilde, Sebastian Dolff, Andreas Kribben

“…Thus, the humoral response of renal transplant recipients after two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech, Kronach, Germany) is impaired and significantly lower compared to healthy controls (22% vs. 100%; <i>p</i> = 0.0001). …”
Get full text

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status by Eyre, DW, Lumley, SF, Wei, J, Cox, S, James, T, Justice, A, Jesuthasan, G, O'Donnell, D, Howarth, A, Hatch, SB, Marsden, BD, Jones, EY, Stuart, DI, Ebner, D, Hoosdally, S, Crook, DW, Peto, TEA, Walker, TM, Stoesser, NE, Matthews, PC, Pouwels, KB, Walker, AS, Jeffery, K

“…Oxford–AstraZeneca vaccine recipients had lower readings post first dose than Pfizer–BioNTech recipients, with and without previous infection, 10 095 (5354–17 096) and 435 (203–962) AU/mL respectively (both p < 0.001 versus Pfizer–BioNTech). …”

The effectiveness of single and two-dose Pfizer-BioNTech vaccine against SARS-COV-2: A real-world evidence from Saudi Arabia by Yasser Albogami, Abdulaziz Alalwan, Mohammed A. Batais, Khaled Alabdulkareem, Abdullah A. Alalwan

“…The sample was relatively young with median age of 22 years and 43% female. A single dose of Pfizer-BioNTech vaccine had 40 % effectiveness. The effectiveness of the vaccine was doubled after the second dose of Pfizer-BioNTech (80 %). …”
Get full text

Trigeminal neuralgia occurring after the third dose of Pfizer BioNTech COVID-19 vaccine. Complication or coincidence?... by Kacper Chrostowski, Michał Piasecki, Joanna Bielewicz

“…The pain appeared two months ago, on the day following the vaccination using the third dose of the Pfizer BioNTech COVID-19 vaccine. At the Neurology Department she was diagnosed with trigeminal neuralgia. …”
Get full text

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine by Rachael K. Raw, Jon Rees, David R. Chadwick

“…Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. …”
Get full text

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine. by Rachael K Raw, Jon Rees, David R Chadwick

“…Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. …”
Get full text

Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies. by Megan Wallace, Jennifer P Collins, Heidi Moline, Ian D Plumb, Monica Godfrey, Rebecca L Morgan, Doug Campos-Outcalt, Sara E Oliver, Kathleen Dooling, Julia W Gargano

“…In December 2020, an interim recommendation for the use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years was made under Food and Drug Administration's Emergency Use Authorization. …”
Get full text

Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar by Khadieja Osman, Jesha Mundodan, Juel Chowdhury, Rejoice Ravi, Rekayahouda Baaboura, Jeevan Albuquerque, Bilal Riaz, Reem Yusuf Emran, Khatija Batoul, Abdul Mahmood Esameldin, Zinah Al Tabatabaee, Hayat Khogali, Soha Albayat

“…The two-dose primary series of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine against SARS-CoV-2 infection has been approved for use in 30 µg formulations among children and adolescents aged 12–17 years as of 16 May 2021. …”
Get full text

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence by Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Get full text

A Mason-Pfizer Monkey virus Gag-GFP fusion vector allows visualization of capsid transport in live cells and demonstrates a role for microtubules. by Jasmine Clark, Petra Grznarova, Elizabeth Stansell, William Diehl, Jan Lipov, Paul Spearman, Tomas Ruml, Eric Hunter

“…Immature capsids of the Betaretrovirus, Mason-Pfizer Monkey virus (M-PMV), are assembled in the pericentriolar region of the cell, and are then transported to the plasma membrane for budding. …”
Get full text

A predictive model to estimate fever after receipt of the second dose of Pfizer‐BioNTech coronavirus disease 2019 vaccine: An observational cohort study by Satoru Chiba, Kaoru Shinohara

“…A total of 153 medical personnel aged 22–86 years of age were involved in the study to receive two doses, intramuscularly 21 days apart, of the Pfizer‐BioNTech COVID‐19 vaccine (30 μg per dose). …”
Get full text

Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine: a report from Turkey by Hayrullah Alp, Melih Timuçin Doğan

“…We present details on a 15-year-old previously healthy Turkish male adolescent who fulfilled the diagnostic criteria for MIS-C after the Pfizer-BioNTech vaccine.…”
Get full text

Effect of Pfizer/BioNTech and Sinovac/CoronaVac Vaccines on Semen Parameters in Infertile Patients with Idiopathic Infertility: A Single-center Cohort Study by Eyüp Dil

Subjects: Get full text

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database by Mansour Tobaiqy, Katie MacLure, Hajer Elkout, Derek Stewart

Subjects: Get full text

Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers by Salvagno Gian Luca, Henry Brandon M., Pighi Laura, de Nitto Simone, Lippi Giuseppe

“…Background: This study aimed at monitoring the kinetics of serum total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in a cohort of healthcare workers after voluntary vaccination with Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA-based vaccine. …”
Get full text

Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia by Zoe L. Lyski, Myung Sun Kim, David Xthona Lee, David Sampson, Hans-Peter Raué, Vikram Raghunathan, Debbie Ryan, Amanda E. Brunton, Mark K. Slifka, William B. Messer, Stephen E. Spurgeon

Get full text